Patents Assigned to Merck
  • Polymerisable compounds and the use thereof in liquid-crystal displays
    Patent number: 10995273
    Abstract: Polymerisable compounds, processes and intermediates for the preparation thereof, liquid-crystal (LC) media comprising them, and the use of the polymerisable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the polymer sustained alignment type.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: May 4, 2021
    Assignee: Merck Patent GmbH
    Inventors: Dmitry Ushakov, Kaja Christina Deing
  • Modulation of tumor immunity
    Patent number: 10994008
    Abstract: Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: May 4, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gu Danling, Amy M. Beebe
  • NOVEL PROCESS FOR SYNTHESIS OF A PHENOXY DIAMINOPYRIMIDINE COMPOUND
    Publication number: 20210122717
    Abstract: Disclosed herein is a novel process for preparing Compound A free base, 5-((2,4-diaminopyrimidin-5-yl)oxy)-4-iso-propyl-2-methoxybenzenesulfonamide, and a citrate salt of Compound A with simplified chemistry and a high overall yield: Compound A. In one embodiment, the overall yield from the starting material 2-isopropylphenol to Compound A citrate salt is greater than 50%. In another embodiment, the overall yield is greater than 60%. Also disclosed herein are novel salts and solvates of Compound A.
    Type: Application
    Filed: April 18, 2019
    Publication date: April 29, 2021
    Applicants: Merck Sharp & Dohme Corp., Werthenstein BioPharma GmbH
    Inventors: Kevin M. Maloney, Kallol Basu, John Y.L. Chung, Richard Desmond, Michael James Di Maso, Guy R. Humphrey, Alfred Y. Lee, Dan Lehnherr, Feng Peng, Hong Ren, Mark Weisel, Siwei Zhang, Patrick Larpent
  • BIOMARKERS FOR A COMBINATION THERAPY COMPRISING LENVATINIB AND A PD-1 ANTAGONIST
    Publication number: 20210123919
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a combination therapy comprising lenvatinib compound and a PD-1 antagonist. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing cancer.
    Type: Application
    Filed: May 13, 2019
    Publication date: April 29, 2021
    Applicants: Merck Sharp & Dohme Corp., Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro FUNAHASHI, Kotaro KODAMA, Ryo DAIRIKI, Yukinori MINOSHIMA
  • DIBENZOFURANS AND DIBENZOTHIOPHENES
    Publication number: 20210122725
    Abstract: The present invention relates to dibenzofuans and dibenzothiophenes thiophenes of formula I in which the occurring groups and parameters have the meanings as indicated in claim 1, to liquid-crystalline media comprising same and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, in particular for microwave phased-array antennas.
    Type: Application
    Filed: October 16, 2018
    Publication date: April 29, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Dmitry USHAKOV, Beate SCHNEIDER, Carsten FRITZSCH, Dagmar KLASS
  • ISOTHIOCYANATO TOLANE DERIVATIVES
    Publication number: 20210122977
    Abstract: The present invention relates to isothiocyanato tolane derivatives of formula I in which the occurring groups have the meanings indicated in claim 1, to a process for their preparation, to liquid-crystalline media comprising same and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, in particular for microwave phased-array antennas.
    Type: Application
    Filed: September 11, 2018
    Publication date: April 29, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Dmitry USHAKOV, Beate SCHNEIDER, Carsten FRITZSCH, Michael WITTEK, Dagmar KLASS
  • Liquid-crystal medium
    Patent number: 10988691
    Abstract: The present invention relates to dielectrically positive liquid-crystalline media comprising one or more compounds of the formula I and II in which the parameters have the respective meanings indicated in claim 1, and to liquid-crystal displays, especially active-matrix displays and in particular displays of the vertically aligned mode, containing these media.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: April 27, 2021
    Assignee: Merck Patent GmbH
    Inventors: Takanori Takeda, Masahiko Okamura, Norihiko Tanaka, Yasushi Sugiyama
  • GCN2 inhibitors and uses thereof
    Patent number: 10988477
    Abstract: The present invention provides compounds inhibiting General amino acid Control Non-derepressible 2 kinase (“GCN2”), compositions thereof, and methods of using the same for treating various disorders, such as cancer.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: April 27, 2021
    Assignees: Merck Patent GmbH, Vertex Pharmaceuticals Incorporated
    Inventors: Andrew Bayly, Matthew Bleich, Jean-Damien Charrier, James Dodd, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Shazia Kelly, Ronald Knegtel, Igor Mochalkin, Michael Mortimore, Kiri North, Filippos Porichis, Robert Pullin, Alistair Rutherford, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • Liquid crystal medium and liquid crystal device
    Patent number: 10988692
    Abstract: The invention relates to a medium comprising at least 60% of one or more compounds of formula I wherein R11, R12, MG11, MG12 and Sp1 have the meaning given herein below, to the use of such media in liquid crystal devices, in particular in flexoelectric liquid crystal devices, and to a flexoelectric liquid crystal device comprising a liquid crystal medium according to the present invention.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: April 27, 2021
    Assignee: Merck Patent GmbH
    Inventors: Simon Siemianowski, Konstantin Schneider
  • Substituted n?-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 10988487
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 27, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kun Liu, Abdelghani Achab, Purakkattle Biju, Timothy A. Cernak, Yongqi Deng, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Joseph Kozlowski, Derun Li, Guoqing Li, Qinglin Pu, Zhi-Cai Shi, Wensheng Yu, Hongjun Zhang
  • Materials for organic electroluminescent devices
    Patent number: 10991892
    Abstract: The present invention relates to carbazole derivatives, in particular for use as triplet matrix materials in organic electroluminescent devices. The invention further relates to a method for producing the compounds according to the invention and to electronic devices comprising same.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: April 27, 2021
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Thomas Eberle, Anja Jatsch, Christof Pflumm, Jonas Valentin Kroeber
  • INTERFERENCE PIGMENTS
    Publication number: 20210115260
    Abstract: The present invention relates to interference pigments based on platelet-shaped substrates which are coated with at least four high refractive layers and to the use thereof, inter alia in paints, coatings, printings inks, plastics and in particular in cosmetic formulations. The interference pigments show a moderate chroma and can be used as effect pigments, as filler pigments and as protection agent against near infrared radiation, VIS and high energy light.
    Type: Application
    Filed: March 14, 2018
    Publication date: April 22, 2021
    Applicant: Merck Patent GmbH
    Inventors: Michael TERMER, Jutta ZUR LAGE, Anett MOSCHNER, Lilia HEIDER
  • TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
    Publication number: 20210115044
    Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: April 22, 2019
    Publication date: April 22, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Tao Yu, James M. Apgar, Alan Whitehead, Yonglian Zhang, Zhiyong Hu, Valerie W. Shurtleff, John A. McCauley, Izzat T. Raheem
  • LIQUID-CRYSTALLINE MEDIUM
    Publication number: 20210115337
    Abstract: The present invention relates to liquid-crystalline media comprising one or more compounds selected from the group of compounds of formula I in which the parameters have the meaning indicated in Claim 1, and to components comprising these media for high-frequency technology, in particular phase shifters and microwave array antennas.
    Type: Application
    Filed: March 13, 2018
    Publication date: April 22, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Michael WITTEK, Dagmar KLASS
  • AGGRECAN BINDING IMMUNOGLOBULINS
    Publication number: 20210115117
    Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.
    Type: Application
    Filed: June 4, 2018
    Publication date: April 22, 2021
    Applicants: Ablynx N.V., Merck Patent GmbH
    Inventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
  • OPITCAL DEVICE COMPRISING A SWITCHABLE LAYER AND AT LEAST ONE OPTICAL LAYER
    Publication number: 20210116748
    Abstract: The invention relates to a switchable optical device (10) having a layer structure comprising at least one switchable layer (15) and at least one optical layer (20, 22). The at least one switchable layer (15) comprises a liquid-crystalline material and at least one dye. The at least one optical layer (20, 22) has at least one reflection band (32) which includes at least a first part of the visible spectrum and has at least one transmission band (30, 34) which includes at least a second part of the visible spectrum. The absorption spectrum of the at least one switchable layer (15) is adjusted by means of the at least one dye such that the light transmission through the switchable optical device (10) for incident light in the visible light spectrum for at least one of the states of the switchable layer (15) is set to a predetermined transmission spectrum.
    Type: Application
    Filed: May 8, 2018
    Publication date: April 22, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Ties DE JONG, Casper VAN OOSTEN
  • Crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
    Publication number: 20210113572
    Abstract: A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be prepared as a pharmaceutical composition.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 22, 2021
    Applicant: Merck Patent GmbH
    Inventors: Michael LANGE, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini
  • Chiral compounds
    Patent number: 10982149
    Abstract: Chiral compounds of formula I wherein the paramters have the meaning given in claim 1, liquid crystal mixtures comprising at least one chiral compound of formula I, to chiral linear or crosslinked liquid crystal polymers obtainable by polymerizing a polymerizable mixture comprising at least one chiral compound of formula I, to the use of chiral compound of formula I and mixtures and polymers obtained thereof in liquid crystal displays, active and passive optical elements, adhesives, synthetic resins with anisotropic mechanical properties, cosmetic and pharmaceutical compositions, diagnostics, liquid crystal pigments, for decorative and security applications, nonlinear optics, optical information storage or as chiral dopants, and a liquid crystal display comprising a mixture comprising at least one chiral compound of formula I.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: April 20, 2021
    Assignee: Merck Patent GmbH
    Inventors: Matthias Bremer, Edward Plummer, Thomas Eichhorn, Peter Schreiner, Christian Kuehn
  • Liquid crystalline medium
    Patent number: 10982150
    Abstract: The present invention relates to liquid crystalline media comprising one or more naphthothiadiazol derivatives of formula I, in which R11, R12, A11, A12, A21, A22, Z11, Z12, Z21, Z22, W, X11, X12, L, r, s and t have the meanings indicated in claim 1, to the use of such liquid crystal media for optical, electro-optical and electronic purposes, in particular in devices for regulating the passage of energy from an outside space into an inside space, for example in windows.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: April 20, 2021
    Assignee: Merck Patent GmbH
    Inventors: Peer Kirsch, Rene Lutz, Michael Junge, Ursula Patwal
  • Domain-exchanged antibody
    Patent number: 10982008
    Abstract: The invention provides for a domain-exchanged antibody comprising a light chain (LC) composed of VL-CH3, and a heavy chain (HC) comprising VH-CH3-CH2-CH3, wherein the VL-CH3 of the LC is dimerising with the VH-CH3 of the HC thereby forming a domain-exchanged LC/HC dimer comprising a CH3LC/CH3HC domain pair, and means and method for producing the same.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: April 20, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Gordana Wozniak-Knopp, Sylvia Dietrich, Florian Rüker, Alec Gross, Stefan Becker